Insulin Glargine (Lantus) Injectable U-100, U-300 Suppliers & Bulk Manufacturers
Available Forms: Vials/pens
Available Strengths: U-100, U-300
Reference Brands: Lantus, Basaglar, Toujeo(US); Lantus, Toujeo(EU)
Category: Diabetes
Insulin Glargine (Lantus) provides a steady, long-lasting release of insulin, mimicking natural basal insulin to regulate blood sugar levels throughout the day. Its benefits include consistent glucose control, reduced risk of hypoglycemia, and improved insulin adherence, making it effective for managing both type 1 and type 2 diabetes.
Product Description:
Insulin Glargine (Lantus) is a long-acting basal insulin approved in the EU and US for managing diabetes. In the EU, it is regulated by the EMA, with Sanofi’s Lantus and Toujeo holding approved dossiers demonstrating safety and efficacy. In the US, the FDA approved Lantus and biosimilars like Basaglar, based on comprehensive clinical data and biosimilarity studies. Both regions require detailed dossiers and ongoing pharmacovigilance for post-marketing surveillance. For expert support with regulatory dossiers and compliance, visit PharmaTradz, your trusted partner in pharmaceutical regulatory services.
Insulin Glargine (Lantus) Injectable — third party manufacturing & bulk supply
Insulin Glargine (Lantus) Injectable U-100, U-300 is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Manufacturers of Insulin Glargine (Lantus) Injectable listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Insulin Glargine (Lantus) Injectable →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Insulin Glargine is a synthetic human insulin analogue produced by recombinant DNA technology using Escherichia coli or Saccharomyces cerevisiae (yeast) cells. The amino acid sequence is modified to provide prolonged, consistent insulin release after injection.
The main trade name of Insulin Glargine is Lantus®.
Other marketed brand names include
The original manufacturer of Lantus® is Sanofi-Aventis.
Other companies manufacturing biosimilar versions include
The generic name is Insulin Glargine.
The brand name is Lantus® (by Sanofi).
Common biosimilar brand names:
Lantus® is manufactured by Sanofi-Aventis at multiple global facilities, including sites in Frankfurt (Germany), Paris (France), and India (Sanofi India Ltd., Goa).
Biosimilars are also manufactured in the
Related Products
Pioglitazone Hydrochloride 150Mg Tablet
Strength:
15 mg, 30 mg, 45 mg
Form: Tablets
Reference Brands: Actos (USA)
View Details
Nateglinide
Strength:
60 mg, 120 mg, 180 mg
Form: Tablets
Reference Brands: Starlix (USA)
View Details
Miglitol
Strength:
25 mg, 50 mg, 100 mg
Form: Tablets
Reference Brands: Glyset (USA), Diastabol (EU)
View DetailsQuick Response Guaranteed | Verified Suppliers
